OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Thoracic Oncology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Pitfalls in Molecular Testing and the Added Value of the Cancer Research Biomedical Community	789
P2.11A.26 Prognostic Utility of Peripheral Myeloid Cells for Clinical Outcomes in Patients with NSCLC Treated with Cemiplimab	392
Meeting Announcements	330
Beyond Personalized to “Tumoralized” Therapy	317
EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study	244
P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy	229
EP08.02-027 T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC	223
P45.14 Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Alterated Non-Small-Cell Lung Cancer Patients in China	213
P37.03 The Epidemic of Malignant Mesothelioma in China: A Prediction of Incidence During 2016-2030	211
In This Issue/Research Watch/News in Brief	195
Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib	186
EP.12A.08 Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A Real-World Study	180
OA16.03 Telisotuzumab Vedotin in Asian Patients with C-Met Protein-Overexpressing Non-Squamous EGFR WT NSCLC: Results from LUMINOSITY	177
P1.01A.01 The INHERIT Study - Investigating Hereditary Risk in Thoracic Cancers (NCT05587439)	173
From the IASLC Tobacco Control Committee	168
In This Issue/Research Watch/News in Brief	159
PP01.26 Proprietary vs Open-Source Radiomic Platform for Lung Cancer Diagnosis	158
PP01.112 Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study	157
PP01.172 It's Never Too Late To Quit	142
213P Development of an explainable clinical decision support tool for advanced lung cancer patients	135
218P Implications of the eighth edition of TNM staging system for thymoma, a single-center retrospective study	130
EP07.01-024 Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma	125
EP07.03-001 Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma	119
P30.02 Salvage Surgery in Patients With Locally Advanced Non-Small Cell Lung Cancer – Outcomes and Longtime Results	117
P33.01 Air Leak Due COVID-19 in a Lung Cancer Patient	113

EP08.01-021 Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy	110
115P Salvage surgery in patients with locally advanced or metastatic non-small cell lung cancer	108
PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis	108
P10.09 Efficacy and Toxicity of EGFR-TKI in Frail NSCLC with EGFR Mutation: A Retrospective Analysis in a Single Institution	105
EP05.01-023 Feasibility of Functional Lung Avoidance using Ga-68 4D Ventilation Perfusion PET/CT: The HI-FIVE Trial	103
P12.01 A Novel 89Zr-α-PD-1 Immuno-PET-CT May Improve Pseudoprogression Detection in a Lung Cancer Murine Model Receiving Immunotherapy	103
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC	99
P23.02 Digital Multiplexed circRNA Analysis From Plasma-Derived Extracellular Vesicles of Lung Cancer Patients	98
EP08.01-055 Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer	97
EP08.01-079 Long Term Use of Immune Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer (NSCLC) and Abnormal Marrow Pathology: A Case Series	97
EP08.01-093 ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer	96
P66.08 Differential Expression of INSM1 Between Pure SCLC and LCNEC After Surgical Resection and Its Clinicopathological Significance	94
EP14.02-006 Subtype-specific Hypersensitivity to Oxidative Phosphorylation Inhibition in Small Cell Lung Cancer	88
OA11.06 Sequencing of ctDNA Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis	86
EP16.03-018 Molecular Features of Subtypes Classified Based on Predominance and Components in Chinese Patients with Lung Adenocarcinoma	86
P66.06 GPNMB Associates With Inferior Prognosis in SCLC Patients Through Promoting Tumor Cell Metastasis	86
EP14.05-019 Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-2021	84
MA04.09 The Incidence and Predictors of Unsuspected Brain Metastases in Patients with Stage IA NSCLC	84
P68.06 Development and Validation of an NGS-Based MSI Detection Method	84
FP02.01 Utilization and Refusal of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: A National Cancer Database Study	81
Table of Contents	80
FP01.02 A Comparative Cost Analysis Study of Robotic and Video-Assisted Lobectomy: Results of Randomized Controlled Trial (Bravo Trial)	80
EP01.01-007 Incorporating cfDNA Detection to CT Scan Assessment in Post-Surgical Lung Cancer Patients	76
EP11.03-004 Identification of Filigree Pattern Increases Diagnostic Accuracy of Micropapillary Pattern on Frozen Section for Lung Adenocarcinoma	74
63P Inflammatory indexes and treatment response as correlates of pembrolizumab effectiveness in patients with PD-L1≥50%: Data from the real-life practice	74
EP01.02-006 Excuse Me? Patient Perceptions of Lung Cancer Screening Results	74
73P Qualitative research to evaluate perceptions around biomarker testing and patient-reported outcomes (PROs) for use in studies of non-small cell lung cancer (NSCLC)	73
FP16.04 A Nationwide Population-Based Mapping of Mutations and Gene Fusions in Lung Cancer Among Never-Smokers	73
P68.18 Relationship Between Cholesterol Synthesis in Cancer Cells and Anticancer Effect of Statins	71
EP01.07-001 Surveillance with FDG PET/CT after Completion of Therapy for NSCLC: A Status Update on Inclusion in the SUPE_R Trial	71
PP.04 EGFR Structure-Based Classification and Presence of Commutations in Peruvian Patients With Advanced Lung Cancer	70
MA02.05 A Phase I Study of Afatinib in Combination With Osimertinib in Patients After Failure of Prior Osimertinib	70
P06.08 Treatment Outcome of Second Primary Lung Cancer	68
50P Patient-reported outcomes in non-small cell lung cancer patients receiving immunotherapy monotherapy: Analysis from enhanced, EHR-facilitated cancer symptom control (E2C2) pragmatic clinical trial	67
25P Furmonertinib plus icotinib for first-line treatment of EGFR-mutated non-small cell lung cancer	67
OA10.04 COVID-19 Vaccine Acceptance and Communications Effectiveness Amongst Canadian Lung Cancer Patients.	67
P2.07-01 Deep-Learning Based Prediction of c-MET Status from Digitized H&E-Stained Non-Small Cell Lung Cancer Tissue Samples	67
European Society of Thoracic Surgeons (ESTS)	65
EP04.01-012 Sex and Age-Related Guideline-Adherence Disparities in Non-Small-Cell Lung Cancer Treatment Patterns: Real-World Data	65
OA08.06 Implementation of a Nurse-led Geriatric Oncology Assessment Model in the Lung Cancer Care Pathway	65
FP14.01 A Phase 1b/2 Study of Autologous Dendritic Cell Vaccination in Combination With Atezolizumab in Patients With Small Cell Lung Cancer (SCLC)	64
EP04.01-001 Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience	63
P07.03 Lung Cancer Under 50 Years Old – What Reality Taught Us	60
MA02.01 Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial	59
EP08.02-119 RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer	58
P59.01 Clinical Characteristics of Patients With MET Amplification-Positive NSCLC After EGFR-TKI Therapy	58
P61.05 Time to Loosen Up: Liberalizing Lung Cancer Screening Guidelines Might Save More Lives	57
Table of Contents	56
Preoperative Biopsy Diagnosis in Patients With Pulmonary Carcinoids: A Biomarker Panel Will Be Crucial to Hit a Bull’s Eye	56
P34.04 Chemo-Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) – Real World Data from a Tertiary Oncology Centre	55

EP08.02-100 Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression	55
P39.05 Outcomes of Videothoracoscopic Thymectomy for Treatment Large-Sized Thymomas	54
P56.01 Semiquantitative Assessment of Tumor Spread Through Air Spaces in a Historic Cohort of Lung Adenocarcinomas Following Open Surgical Resection	54
EP.08F.18 Survival and Incidence Trends of Non-Small Cell Lung Cancer in Elderly Patients (>75 Years): Insights from SEER Database	53
Rethinking Biomarkers for Combination Chemoimmunotherapy	53
P3.08E.01 Perioperative Chemoimmunotherapy Rescue Cold HLA-Deficient Tumors Inducing Strong Immune Responses and Long-Term Survival	52
EP.07A.08 Modified Periareolar Incision for Uniportal Segmentectomy	52
EP.11A.16 Infusion Timing of ICI Monotherapy in Patients with Advanced NSCLC: A Single Institution-Retrospective Study	50
EP.04A.16 Cost-Effectiveness of Adaptive Schedules for Lung Cancer Screening: A Modeling Study	50
EP.12A.39 MET Point Mutations as the Mechanism of Resistance to EGFR-TKI Therapy: A Case Report of MET H1094Y-Mediated Resistance to Osimertinib Overcome by Capmatinib and a Systematic Review.	50
EP.07E.02 Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer	50
MA07.09 Genome-Wide CRISPR Screen Identifies SFRP2 as a Novel Stromal Target to Enhance Abscopal Effect of Radioimmunotherapy	49
EP.13D.07 Impact of Antiemetic Steroid Use on Survival in Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors and Chemotherapy Combination	49
EP.15B.04 High-Fiber Intake Predicts Overall Survival in Lung Cancer Patients - Real-World Analyses	49
EP.08D.06 Neoadjuvant Chemoimmunotherapy Does Not Increase Postoperative Morbidity of Pneumonectomy in NSCLC Patients: A Multi-Center Psmanalysis	48
MA11.13 Peripheral T-Cell Receptor Repertoire Differentiates a Typical Progression in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy	47
P2.11C.01 With Eyes on the Future: Prospective Evaluation of Immune-Related Adverse Events in Patients with Lung Cancer	47
P4.11D.05 EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy	47
P4.11E.13 Real-World Treatment Patterns, Healthcare Cost and Resource Utilization in First-Line Treatment of Metastatic NSCLC in the US	46
P2.11A.23 Fecal Microbiota Transplantation Plus Rechallenging Immunotherapy in Patients with Advanced Non Small Cell Lung Cancer: An Exploratory Study	46
EP.12A.10 Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients	45
EP.14C.08 Challenges in Diagnosis and Management of Epithelioid Inflammatory Myofibroblastic Sarcoma - Case Report	45
EP.16A.01 Patient Experiences of Biomarker Testing: Insights from a Global Patient Experience Survey	45
P2.17B.02 Healthcare Providers' Perceptions of Barriers and Enablers to Adopting New Surveillance Protocols	45
Response to Letter to the Editor From Binghao Zhao et al	44
Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response	44
Iruplinalkib (WX-0593), the Seventh ALK Tyrosine Kinase Inhibitor Approved in People's Republic of China With More to Come	44
Editorial Board	44
Board of Directors	43
Comment on “MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC”	43
Bidirectional Association Between Cardiovascular Disease and Lung Cancer in a Prospective Cohort Study	42
Why and When Do We Invasively Restage After Neoadjuvant Chemoimmunotherapy?	42
P06.02 Incorporating Surgical Collapse in the Pathological Assessment of Resected Adenocarcinoma in situ of the Lung. A Proof of Principle Study	41
EP08.02-163 Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer	41
Lung Cancer in Nepal	40
P1.26-05 Sublobar Resection is Equivalent to Lobectomy for Stage IA Adenocarcinoma Presenting as Subsolid Nodule	40
Lung Cancer in Romania	40
EP05.01-04 A Retrospective Study on the Efficacy and Safety of Flexible Bronchoscopy in Elderly Patients with Suspected Primary Lung Cancer	39
P1.16-03 Transbronchial Cryobiopsy Using 1.1 mm-Diameter Cryoprobe for the Diagnosis of Early Stage Lung Cancer	39
P1.22-02 Whole Genome Sequencing Analysis of ALK-rearranged Non-small Cell Lung Cancer	39
EP07.02-15 Longitudinal ctDNA Testing in Resected, Early Stage Non-small Cell Lung Cancers	38
EP14.03-12 Anastomosing Hemangioma of Mediastinum and Pleura Mimicking Chest Malignancy	38
EP14.03-07 Three Cases of Mediastinal Teratoma Resulting in Thoracic Perforation	38
EP12.01-73 Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy	38
EP04.04-05 Ten-year CTNB Data Indicate Its Usefulness and Safety, Especially Salvage Situation after Bronchoscopy without Diagnosis	37
EP11.03-31 Quantification of Interstitial Lung Abnormality Using Deep Learning in Cancer Patients Who Underwent Immune Checkpoint Inhibitors	37
EP07.04-17 Study on the Regulatory Mechanism of OM-85 BV on the Immune Microenvironment of Clinical Early-stage Lung Adenocarcinoma	37
MA10.05 Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review	36
WS08.07 Evaluation of a Risk-sharing Agreement for Atezolizumab Treatment in NSCLC Patients: A Strategy to Improve Access in Low Income Countries	36
OA04.06 The Global Landscape of Lung Squamous Cell Carcinoma, Lung Adenocarcinoma, Small Cell Lung Cancer Incidence in 2020	36
EP13.01-10 Mitotic Counts and Phospho-Histone H3 Index in Grading Pulmonary Neuroendocrine Tumors: Assessment of Interobserver Variability and Utility	36
EP04.06-04 Impact of a Navigational Program on Lung Cancer Screening at a Community Health Center Serving an Urban Diverse Population	36
OA12.03 An Analysis of the Rate of Second Primary Lung Cancer from CALGB (Alliance) 140503 Trial of Lobar versus Sub-Lobar Resection for T1aN0 NSCLC	36
EP11.03-39 Platinum/Taxane versus Docetaxel +/- Ramucirumab for Metastatic Lung Cancers That Progressed on Platinum Doublets and Anti-PD1/PD-L1	35
The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven	35
EP11.04-01 Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer	35
P2.07-08 Checkpoint Inhibitor Pneumonitis Model for NSCLC based onPreexistingLung Ground Glass Opacities: Development and Validation	34
OA15.05 Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC	34
EP05.01-11 Lung Cancers Diagnosed in a Retrospective Cohort of Lung Nodule Patients in Singapore	33
P1.26-06 Harmonized Maximum Standardized Uptake Value as an Indicator for Sublobar Resection: A Multicenter Retrospective Study	33
EP07.04-10 Early-Stage EGFR Mutated NSCLC: Outcomes After Surgical Resection at a Large Academic Medical Center	33
P1.25-15 Trends and Disparities in Curative-Intent Treatment for Early-Stage Non-Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT	33
P1.25-13 Enhanced Assessment Of Recurrence Risk Of Stage I NSCLC By Combined Adenocarcinoma Grading System And Serum Proteomic Testing	33
MA03.06 Respiratory Tract Malignancy-associated Mortality Attributable to Particulate Matter in South Asia from the Global Burden of Disease	33
MA17.05 Real World Outcomes of Immunotherapy (IO) for Pleural MESOthelioma in Australia - RIOMeso	32
P2.13-02 Molecular Subtyping of Small Cell Lung Carcinoma: An Attempt at Unravelling Its Biological Heterogeneity	32
EP01.01-09 Radiation Exposure in Intraoperative Navigation for Peripheral Small Pulmonary Nodule	32
P1.21-11 Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%	32
P1.25-07 Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR	32
EP12.01-44 A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib	32
EP03.03-06 The Involvement of Tumor Endothelial Cells in the Regulation of PD-L1 and Tregs in the Immune Microenvironment of Early-stage Lung Adenocarcinoma	32
P2.01-05 The Safety and Efficacy of Induction Chemoimmunotherapy Followed by Radiotherapy and Consolidation Immunotherapy in Locally Advanced NSCLC	32
P1.05-01 Research on Specific DNA Methylation Regulatory Mechanism Based on Pan-Cancer Analysis	32
EP03.02-03 High-Throughput Screening Reveals Ceritinib as a Sensitizer for Cafs-Induced Osimertinib Resistance in Non-small Cell Lung Cancer	32
P2.20-05 The Impact of Preoperative Immunotherapy On Peri-Operative Outcomes After Thymectomy for Thymic Epithelial Tumors	32
EP.02A.02 The Stroma Cell Function in the Border Region Between Lung Cancer and Normal Lung	31
P2.17-02 EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study	31
In Response to Continuation of Lorlatinib Beyond Progressive Disease	31
PP01.25 Exploring the Impact of Socioeconomic and Geographic Factors on Immunotherapy Discontinuation and Success in Northern Ontario: A Retrospective, Single-Center Cohort Study	31
Establishment of Tumor Immune Microenvironment Classification Model to Select Patients Sensitive to Immunotherapy	31

EP12.01-62 Osteoblastic Bone Reaction in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Treated with Osimertinib	31
EP01.04-001 A Programmatic Approach to Improve Efficiency in Lung Cancer Screening	31
P3.03I.08 Efficacy of Novel Third-Generation Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations- Anin Vitrostudy	30
P2.14A.10 Real-World Evidence of Ipilimumab Plus Nivolumab Combination Therapy in Patients with Malignant Pleural Mesothelioma	30
P1.08C.05 The Clinicopathological and Prognostic Significance of Skip-N2 Metastases: A Retrospective Multicenter Study	30
P2.04A.07 Improving IPN Management Through CAD and Virtual Nodule Clinics: A Prospective, Observational Multicenter Study (PINPOINT)	30
EP.07F.06 Prospective Study of Breath Hold During SBRT Treatment of the Lung: Analysis Reliability of Surface Guidance Alone for Breath Hold	30
EP.04A.01 Lung Cancer Nurse Consultant-Led Pulmonary Nodule Assessment and Surveillance Clinic: Multidisciplinary Team Evaluation	29
P2.17B.03 Improving Lung Cancer Screening Utilization and Efficiency Through a Patient-Centered Pathway with Virtual Visits	29
P1.01C.04 Key Stakeholder Priorities on Embedding Smoking Cessation Into Lung Cancer Screening: National Australian Consensus Workshop	29
MA04.05 An Evolution and Expanding Engagement to Excel in Lung Cancer Screening	29
MA18.09 Comparing Efficient Lung Cancer Screening Strategies for Black and White Americans	29
Meeting Announcements	28
P4.11E.02 Efficacy of Pembrolizumab Plus Pemetrexed in Older Patients with Non-squamous NSCLC According to PD-L1 Status from the CJLSG1901 Study	28
EP.12A.22 Aumolertinib with Chemotherapy as First-Line Treatment in Patients with EGFR-Mutated Advanced NSCLC: A Real-World Study	28
EP.06D.02 Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib	28
EP.11A.05 Use of Immune Checkpoint Inhibitors in Advanced NSCLC Cases with Very Poor ECOG-PS: A Real World Experience	28
MA01.04 AFT-46: CHIO3: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer	28
EP17.04-01 The Impact of the Emergency Presentation of Patients Diagnosed with Lung Cancer on Treatment Outcomes in Wales	27
EP.03F.05 A Dose-Effect Relationship of a Novel Bronchoscopy Guided Endobronchial Radiofrequency Ablation for Peripheral Lung Tumors	27
P49.01 Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC	27
Editorial Board	27
Editorial Commentary: Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC	27
390P: Evaluate the effects of VMAT and IMRT treatment techniques on critical organs with different treatment planning algorithms	26
OA01.06 A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer	26
181P: Evaluating probe-based confocal laser endomicroscopy for lung nodule diagnosis: A comprehensive systematic review and meta-analysis	26
422P: Acute pneumonitis in patients receiving thoracic radiotherapy and pre-treated with immune checkpoint inhibitors	26
60P: The FIN-EGFR study: A retrospective observational study to investigate the treatment landscape and outcomes of early and advanced stage patients with EGFR mutated non-small cell lung cancer (NSCL	26
Predicted Effect of Incidental Pulmonary Nodule Findings on NSCLC Mortality	25
253P: Surgical vs non-surgical management of non-small cell lung cancer with brain metastases	25
357P: Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC)	25
Current and Future Treatment Options in the Management of Stage III NSCLC	25
312P: Correlation between immune-related adverse events (irAEs) and survival outcomes in extensive-stage small cell lung cancer (ES-SCLC) patients (pts) treated with chemoimmunotherapy (CT-IO)	25
27P: Impact of platinum-based chemotherapy (CT) on acquired resistance (AR) to first-line immunecheckpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC): Individual patient data metanalysis	25
Board of Directors	25
348P: Pulsed high-dose fractionated radiotherapy combined with enhanced immunotherapy in the treatment of driver gene-negative advanced non-small cell lung cancer: A clinical study	25
273P: Effect of lung cancer screening, smoking cessation and cessation smartphone application to health-related quality of life	25
32P: The impact of renal dysfunction and pemetrexed administration dose in KEYNOTE189 on prognosis	25
Meeting Announcements	24
Lung Cancer in Japan	24
Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort	24
OA10.03 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up	24
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer	23
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial	23
OA09.01 First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA	23
The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification	23
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study	23
Selective Depletion of CCR8+Treg Cells Enhances the Antitumor Immunity of Cytotoxic T Cells in Lung Cancer by Dendritic Cells	23
EP01.06-002 Impact of Immediate AI Enabled Patient Triage to Chest CT on the Lung Cancer Pathway: LungIMPACT	23
P53.05 Inhibition of Tumor Cell Intrinsic Complement Regulatory Proteins Leads to Decreased Tumor Growth in a Mouse Model of NSCLC	23
Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis	22
Tobacco News Update - From the IASLC Tobacco Control Committee	22
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion	22
Revisiting “BAP1ness” in Malignant Pleural Mesothelioma	21
P62.10 AI-Based Three-Dimension Reconstruction for Pulmonary Nodules -New Auxiliary Exploration for Thoracic Surgery	21
Lung Cancer in Armenia	21
From the IASLC Tobacco Control Committee	21
Lung Cancer in Vietnam	21
Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?	21
Board of Directors	21
60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treat	21
Editorial Board	21
Meeting Announcements	21
Erratum	21
Response to “Revisiting ‘BAP1ness’ in Malignant Pleural Mesothelioma”	21
EP08.02-171 PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion‒Positive Metastatic Non‒Small Cell Lung Cancer (NSCLC)	20
MA06.09 Deep Learning for Predicting MPR to Neoadjuvant Immunotherapy in NSCLC	20
EP16.02-006 Evaluation of Carcinoembryonic Antigen (CEA) as Predictive Marker in Patients with Metastatic Non-small Cell Lung Cancer	20
P61.03 Comparison of the Sensitivity of Different Screening Algorithms to Select Lung Cancer Patients for Screening in a Cohort of German Patients	20
EP08.03-001 A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases	20
EP11.01-012 Genomic Landscape of Liquid Biopsy in Advanced Lung Cancer Patients, an Indian Experience	20
PD.01.02 Novel MicroRNAs Identified in Lung Cancer and Associated With Malignant Metabolism (In Silico)	20
EP02.01-012 PD-L1 Expression Predicts Prognosis in Completely Resected NSCLC Patients with an EGFR Mutation	19
MA04.01 Multimodality Treatment and Outcome in Stage III Thymic Epithelial Tumors (TETs): A Retrospective Analysis From the French RYTHMIC Network	19
EP08.05-004 The Optimal Intervention Timing of Hypofractionated Stereotactic Radiotherapy for EGFR Mutated NSCLC Patients With Limited Brain Metastases	18
EP13.01-017 Assessing Variance Between Radiology versus Multidisciplinary Clinic Recommendations in the Pulmonary Nodule and Lung Screening Clinic	18
P70.12 NTRK Gene Fusion in Advanced Non Small Cell Lung Cancer at Pham Ngoc Thach Hospital - Viet Nam	18
86P KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma	18
P2.13-01 Low EV miR-30c Levels as Biomarker of Increased Tumor Autophagy and Chemoradiotherapy Resistance in Locally Advanced NSCLC	18
EP14.01-013 First-Line Chemotherapy vs Chemoimmunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung, a Retrospective Study	18
Table of Contents	18
P61.02 The Use of PLCOm2012 vs PLCOm2012noRace Risk Prediction Models in a UK Lung Cancer Screening Programme	18
FP12.07 Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients	18
P19.02 Sintilimab Plus Docetaxel in Previously Treated Advanced NSCLC, Updates on Progression-Free and Overall Survival	18
PP.12 Access to Molecular Testing and Factors to Implement Targeted Therapy in a Brazilian Public Health Service	18
High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study	17
OA12.05 APOLO: Phase II Trial of Induction Chemo-Immunotherapy Plus Chemoradiotherapy and Maintenance Immunotherapy in Stage III NSCLC	17
EP07.01-012 Ipilimumab and Nivolumab in Pretreated Patients with Malignant Pleural Mesothelioma	17
137P Repurposing drug screen of patient-derived malignant pleural mesothelioma cells reveals potential anti-cancer activity	17
Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer	17
Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations	17
EP07.03-003 First Line Combination of Toripalimab and Chemotherapy in Advanced Thymic Carcinoma: A Single-Center, Prospective, Single-Arm, Phase II Trial	17
136P Germline testing in a cohort of malignant mesothelioma (G-MESO)	17
EP08.02-116 Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors	17
P12.03 The Time of Anti-PD-1 Infusion Improves Survival Outcomes by Fasting Conditions Simulation in Non-Small Cell Lung Cancer	17